MID-VOLUME · HOSP-HEAVY
canagliflozin Side Effects
canagliflozin (also sold as Invokana) sits MID-VOLUME #193 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 35.9% mention hospitalization (10,619 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 29,554
- FAERS reports
FDA Adverse Event Reporting System extract for canagliflozin. Stamp set CASELOAD · DEATH-MARKED · HOSP-HEAVY. How figures are compiled.
canagliflozin: 35.9% mention hospitalization (10,619 reports). Death stamp DEATH-MARKED; volume band MID-VOLUME #193 of 524 by FAERS report count.
Mid-book FAERS page for canagliflozin (Invokana) (29,554 reports). Signature HOSP-HEAVY. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2011–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
DIABETIC KETOACIDOSIS leads 3,421 of 29,554 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (9,573 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 678 reports (2.3% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 235 |
| ACUTE KIDNEY INJURY | 80 |
| DIABETIC KETOACIDOSIS | 65 |
| MYOCARDIAL INFARCTION | 38 |
| SEPSIS | 30 |
| CARDIAC ARREST | 27 |
| RENAL FAILURE | 27 |
| HYPOTENSION | 23 |
| LEG AMPUTATION | 22 |
| PNEUMONIA | 22 |
| URINARY TRACT INFECTION | 22 |
| WEIGHT DECREASED | 22 |
| DECREASED APPETITE | 20 |
| DIARRHOEA | 20 |
| OSTEOMYELITIS | 20 |
| DEHYDRATION | 19 |
| FATIGUE | 19 |
| SEPTIC SHOCK | 19 |
| TOE AMPUTATION | 19 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (10,619, 35.9% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| DIABETIC KETOACIDOSIS | 2,850 |
| OSTEOMYELITIS | 1,816 |
| ACUTE KIDNEY INJURY | 1,680 |
| TOE AMPUTATION | 1,649 |
| GANGRENE | 956 |
| CELLULITIS | 906 |
| DIABETIC FOOT INFECTION | 756 |
| LEG AMPUTATION | 668 |
| DIABETIC FOOT | 664 |
| SEPSIS | 543 |
| FOOT AMPUTATION | 491 |
| DEHYDRATION | 398 |
| SKIN ULCER | 387 |
| URINARY TRACT INFECTION | 358 |
| METABOLIC ACIDOSIS | 331 |
| VOMITING | 285 |
| NAUSEA | 281 |
| KETOACIDOSIS | 274 |
| FOURNIER^S GANGRENE | 254 |
How to read canagliflozin FAERS figures (CASELOAD · DEATH-MARKED · HOSP-HEAVY)
FAERS holds 29,554 voluntary reports linked to canagliflozin (Invokana), 2011-2025. Death is listed on 678 (2.3%). Hospitalization appears on 10,619 (35.9%). Top co-reported indication: Type 2 Diabetes Mellitus.
Mid-volume extract - treat DEATH-MARKED · HOSP-HEAVY as signal-detection rates next to 35.9% mention hospitalization (10,619 reports).
Read with canagliflozin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-HEAVY stamps.
ABS(total_reports) peer at 29,404 FAERS cases (Δ 150 lighter vs canagliflozin); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 29,380 FAERS cases (Δ 174 lighter vs canagliflozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 29,813 FAERS cases (Δ 259 heavier vs canagliflozin); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 29,874 FAERS cases (Δ 320 heavier vs canagliflozin); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.8 pp vs canagliflozin's DEATH-MARKED): CASELOAD · HOSP-MID.
canagliflozin stamps DEATH-MARKED · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.